OncoZenge AB (publ) (ONCOZ.ST)
SEK 3.97
(4.34%)
SEK 3.97
(4.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -12.62 Million SEK | 56.67% |
| 2022 | -29.14 Million SEK | 43.11% |
| 2021 | -51.21 Million SEK | -412.23% |
| 2020 | -9.99 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -9.66 Million SEK | 23.48% |
| 2024 Q2 | -7.56 Million SEK | 21.66% |
| 2023 Q1 | -23.79 Million SEK | 18.36% |
| 2023 Q4 | -12.62 Million SEK | 20.79% |
| 2023 Q2 | -20.21 Million SEK | 15.01% |
| 2023 FY | -12.62 Million SEK | 56.67% |
| 2023 Q3 | -15.94 Million SEK | 21.16% |
| 2022 FY | -29.14 Million SEK | 43.11% |
| 2022 Q2 | -34.46 Million SEK | 15.5% |
| 2022 Q4 | -29.14 Million SEK | 11.19% |
| 2022 Q1 | -40.79 Million SEK | 20.36% |
| 2022 Q3 | -32.81 Million SEK | 4.8% |
| 2021 Q2 | -55.57 Million SEK | -6.97% |
| 2021 FY | -51.21 Million SEK | -412.23% |
| 2021 Q4 | -51.21 Million SEK | 8.0% |
| 2021 Q3 | -55.67 Million SEK | -0.17% |
| 2021 Q1 | -51.95 Million SEK | 0.0% |
| 2020 FY | -9.99 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 74.757% |
| Ziccum AB (publ) | -2.13 Million SEK | -490.875% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 33.751% |
| BioArctic AB (publ) | -606.58 Million SEK | 97.918% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 74.713% |
| Mendus AB (publ) | -96.29 Million SEK | 86.887% |
| Genovis AB (publ.) | -43.94 Million SEK | 71.264% |
| Intervacc AB (publ) | -88.16 Million SEK | 85.677% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 161.565% |
| Active Biotech AB (publ) | -33.2 Million SEK | 61.967% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 123.725% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 67.937% |
| Aptahem AB (publ) | 2.9 Million SEK | 534.12% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 96.215% |
| Kancera AB (publ) | -45.69 Million SEK | 72.365% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 96.163% |
| Fluicell AB (publ) | -2.76 Million SEK | -357.003% |
| Saniona AB (publ) | 40.44 Million SEK | 131.219% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 60.45% |
| Biovica International AB (publ) | -58.73 Million SEK | 78.502% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 72.075% |
| AcouSort AB (publ) | -23.98 Million SEK | 47.357% |
| Xintela AB (publ) | -7.8 Million SEK | -61.698% |
| Abliva AB (publ) | -57.24 Million SEK | 77.94% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 93.515% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 84.639% |
| Amniotics AB (publ) | -5.63 Million SEK | -124.201% |
| 2cureX AB (publ) | -13.4 Million SEK | 5.79% |
| CombiGene AB (publ) | -101.44 Million SEK | 87.552% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -484.313% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 333.833% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.916% |
| Corline Biomedical AB | -17.01 Million SEK | 25.776% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 84.922% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 90.86% |
| I-Tech AB | -83.26 Million SEK | 84.835% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 109.374% |
| Cyxone AB (publ) | -16.67 Million SEK | 24.253% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 77.406% |
| Biosergen AB | -1.88 Million SEK | -570.579% |
| Cantargia AB (publ) | -139.74 Million SEK | 90.964% |
| NextCell Pharma AB | -46.79 Million SEK | 73.014% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 90.249% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 57.026% |
| Nanologica AB (publ) | -9.38 Million SEK | -34.501% |
| SynAct Pharma AB | -61.75 Million SEK | 79.554% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 41.037% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 4.552% |
| LIDDS AB (publ) | -13.51 Million SEK | 6.55% |
| Lipum AB (publ) | -8.46 Million SEK | -49.167% |
| BioInvent International AB (publ) | -236.3 Million SEK | 94.656% |
| Alzinova AB (publ) | -21.22 Million SEK | 40.512% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 81.131% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -143.721% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 84.921% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -1268.039% |
| Simris Alg AB (publ) | 85.07 Million SEK | 114.842% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 84.617% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 107.603% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 39.273% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -324.865% |